Navigation Links
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:6/26/2009

, ankles, feet, lower back and neck are commonly affected. Psoriasis affects an estimated two to three percent of the world's population, and approximately one out of three patients affected by psoriasis may develop psoriatic arthritis. Both men and women are equally affected by psoriatic arthritis, most commonly between the ages of 30 and 50, in the peak of their productive years.

About Ankylosing Spondylitis

Ankylosing spondylitis is a painful and progressive form of spinal arthritis, and symptoms of inflammatory back pain often first present in people under the age of 35 years. On the European continent, it is estimated that prevalence ranges from 0.2 to one percent of the entire population. It typically begins in the late teens and early 20s, and in severe cases can result in fusing of the spinal vertebrae and cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision.

About SIMPONI

SIMPONI is a human monoclonal antibody that targets and neutralizes excess TNF alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation and damage to bones, cartilage and tissue. Upon approval in the European Union, SIMPONI will be the first once-monthly subcutaneous anti-TNF-alpha therapy for the treatment of moderate-to-severe, active RA, active and progressive PsA and severe, active AS, and will be available either through the SIMPONI SmartJect(TM) auto injector or a prefilled syringe. The approved dose for SIMPONI in the US and Canada is a 50 mg subcutaneous injection given once a month.

Important Safety Information

In Europe, SIMPONI is contraindicated in patients with active tuberculosis, severe infections such as sepsis, oppo
'/>"/>

SOURCE Schering-Plough Corporation; Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
2. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
3. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
4. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
5. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
6. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
7. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
8. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
9. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
10. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
11. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... (FDA) accepted the company,s Investigational New Drug (IND) application ... efficacy of AVP-786, Avanir,s next generation compound. The company ... adjunctive treatment of major depressive disorder (MDD) during the ... endorsement of this Phase II study by the division ...
(Date:7/21/2014)... 21, 2014 Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and its associated pain, ... the preclinical development of a small molecule inhibitor targeting ... The Myc protein has also been recognized as an ... is involved as a dominant factor in most human ...
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Inc. (OTCPK: SNDY) is pleased to announce that the Company ... in the amount of $90,005. The revenue for the three ... fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers ... growth in 2011 through new product development, new product sales ...
... Ireland, Jan. 27, 2011 Tibotec Pharmaceuticals today ... to generic manufacturers including Hetero Drugs Limited, Matrix ... Aspen Pharmacare of South Africa to manufacture, market ... rilpivirine hydrochloride (TMC278), pending ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 3Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 4
(Date:7/22/2014)... (PRWEB) July 22, 2014 Garland’s new ... is designed to be used as a flood coat ... systems or as a premium restoration material. It provides ... the long-term performance and reducing life-cycle costs. Energizer BK ... to provide excellent water resistance in addition to superior ...
(Date:7/22/2014)... The hair transplant experts at WeGrowHair.com ... assisted laser therapy and robotic assisted hair transplantation ... women suffering from hair loss. Alongside their unique ... Unit Extraction (FUE) procedures via ARTAS – the ... technology, their doctors use advanced digital mapping to ...
(Date:7/21/2014)... sports in the United States, with more than 170,000 ... participation numbers, however, mean that more young people than ... and competition. , In a study published online today ... and available in an upcoming print issue, researchers from ... Children,s Hospital and the Colorado School of Public Health ...
(Date:7/21/2014)... July 21, 2014 As reported by ... Westin Hotel to Raise Addiction Awareness (7/15), thrill-seeking participants ... down a 27-story building in Downtown Philly. 100 people, ... event at the Westin Convention Center Hotel. Some of ... addiction. One man participated because his son killed himself ...
(Date:7/21/2014)... who have a clot in their legs and ... blood-thinning medication or undergo a minimally-invasive catheter-based clot ... no difference in death rates between the two ... the catheter procedure, according to a study by ... involved a review of more than 90,000 cases ...
Breaking Medicine News(10 mins):Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4
... international HIV and AIDS charity AVERT is today launching Stop ... to the 380,000 child AIDS deaths and half a ... ,At this year's G8 summit in Germany, the leaders ... to stop child AIDS deaths by committingspecific funds for prevention ...
... mental well being of young children of today seems to ... NCH, the childrens charity, found that one in ten ... significant level. ,The research says that More than a ... number in a generation. Emotional problems and conduct disorders have ...
... Washington University School of Medicine in St. Louis have ... by revealing that smoking interferes with ligament healing. ... model and found that cigarette smoking impairs the recruitment ... following ligament repair surgery. ,The researchers ...
... More than 60 people had to be treated in hospital ... a polluted Chinese river, state media reported Wednesday. ... their clothes in the Jindong River in eastern Anhui province ... few hours later, Xinhua news agency reported. ,The ...
... have found that a particular resonance pattern in the ... ability to discriminate speech. ,In the ... and Huan Luo report that the inherent rhythm of ... sentences by changing its phase. ,The researchers ...
... recalls how she lost her father, mother and father-in-law to ... to Panama from China. "It's very painful. The three had ... she says, her voice shaking with emotion. ,The ... found to be tainted. At least 80 people in Panama ...
Cached Medicine News:Health News:AIDS Charity AVERT Launches Stop AIDS in Children Campaign 2Health News:Mental Health of Children on the Decline 2Health News:Smoking Hampers Healing of the Ligament 2Health News:Dozens of Panamanians Gravely Ill from Toxic Substance from China 2